Published in Spine (Phila Pa 1976) on December 15, 2012
Inpatient rehabilitation outcomes in patients with malignant spinal cord compression compared to other non-traumatic spinal cord injury: A population based study. J Spinal Cord Med (2015) 0.99
Scoring system for prediction of metastatic spine tumor prognosis. World J Orthop (2014) 0.97
Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants. PLoS One (2013) 0.89
Analysis of the predictive role and new proposal for surgical strategies based on the modified Tomita and Tokuhashi scoring systems for spinal metastasis. World J Surg Oncol (2014) 0.86
Prediction of survival prognosis after surgery in patients with symptomatic metastatic spinal cord compression from non-small cell lung cancer. BMC Cancer (2015) 0.82
Variation in Practice Patterns of Korean Radiation Oncologists for Spine Metastasis between 2009 and 2014. Cancer Res Treat (2015) 0.82
Controversies on individualized prostate cancer care: gaps in current practice. Ther Adv Urol (2013) 0.76
Factors associated with improved survival following surgical treatment for metastatic prostate cancer in the spine: retrospective analysis of 29 patients in a single center. World J Surg Oncol (2016) 0.75
Metastatic spinal cord compression as the first sign of malignancy. Acta Orthop (2017) 0.75
Systematic Review of the Outcomes of Surgical Treatment of Prostate Metastases to the Spine. Global Spine J (2017) 0.75
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One (2011) 3.59
Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ (2009) 3.00
Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate (2004) 2.19
Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol (2007) 1.93
Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol (2013) 1.91
Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol (2012) 1.88
Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study. Int J Cancer (2011) 1.86
Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol (2011) 1.80
Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol (2009) 1.72
Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol (2006) 1.66
The prevalence of neck pain: a population-based study from northern Sweden. Acta Orthop Scand (2002) 1.54
Living with untreated localized prostate cancer: a qualitative analysis of patient narratives. Cancer Nurs (2003) 1.52
The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome. Eur Urol (2005) 1.43
Reclaiming wellness--living with bodily problems, as narrated by men with advanced prostate cancer. Cancer Nurs (2006) 1.43
[Swedish medical research does not need more control]. Lakartidningen (2014) 1.39
S100A9 interaction with TLR4 promotes tumor growth. PLoS One (2012) 1.37
Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate (2009) 1.37
Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. Int J Cancer (2005) 1.37
Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia (2009) 1.33
Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate (2002) 1.30
Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One (2010) 1.28
Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res (2005) 1.24
A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol (2004) 1.22
Blood platelets contain tumor-derived RNA biomarkers. Blood (2011) 1.21
Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol (2010) 1.19
Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS One (2010) 1.19
Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate (2005) 1.18
Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate (2009) 1.17
A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer (2008) 1.17
Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res (2004) 1.16
Low back pain, lifestyle factors and physical activity: a population based-study. J Rehabil Med (2008) 1.16
Genome-wide scan of Swedish families with hereditary prostate cancer: suggestive evidence of linkage at 5q11.2 and 19p13.3. Prostate (2003) 1.15
Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res (2010) 1.15
Gender differences in lumbar disc herniation surgery. Acta Orthop (2008) 1.12
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm (2009) 1.10
TGFβ-induced invasion of prostate cancer cells is promoted by c-Jun-dependent transcriptional activation of Snail1. Cell Cycle (2014) 1.09
Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment. Prostate (2007) 1.09
Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PLoS One (2010) 1.08
One-carbon metabolism and prostate cancer risk: prospective investigation of seven circulating B vitamins and metabolites. Cancer Epidemiol Biomarkers Prev (2009) 1.07
Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate. PLoS One (2009) 1.07
Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate (2005) 1.05
A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model. Prostate (2007) 1.05
LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. Int J Cancer (2011) 1.01
Castration-induced epithelial cell death in human prostate tissue is related to locally reduced IGF-1 levels. Prostate (2007) 1.00
Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target. Expert Opin Ther Targets (2009) 0.98
Solitary fibrous tumor of the prostate: a report of two cases. Pathol Int (2011) 0.98
The incidence of whiplash trauma and the effects of different factors on recovery. J Spinal Disord Tech (2003) 0.98
Outcome after surgery for metastatic spinal cord compression in 54 patients with prostate cancer. Acta Orthop (2011) 0.98
Targeting the endocannabinoid system for the treatment of cancer--a practical view. Curr Top Med Chem (2010) 0.96
Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha. BJU Int (2007) 0.96
Mesenchymal stromal cells from primary osteosarcoma are non-malignant and strikingly similar to their bone marrow counterparts. Int J Cancer (2010) 0.96
Tumour Cannabinoid CB(1) receptor and phosphorylated epidermal growth factor receptor expression are additive prognostic markers for prostate cancer. PLoS One (2010) 0.94
Increased levels of macrophage-secreted cathepsin S during prostate cancer progression in TRAMP mice and patients. Cancer Genomics Proteomics (2009) 0.93
Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11 380 men with serum PSA level 20-100 ng/mL. BJU Int (2012) 0.93
Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance. Scand J Urol Nephrol (2012) 0.93
Tumor indicating normal tissue could be a new source of diagnostic and prognostic markers for prostate cancer. Expert Opin Med Diagn (2010) 0.93
Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome. Am J Pathol (2011) 0.93
Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice. Prostate (2004) 0.92
Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. Eur Urol (2005) 0.92
Do perceptions of adverse events differ between patients and physicians? Findings from a randomized, controlled trial of radical treatment for prostate cancer. J Urol (2010) 0.92
Chronic neck pain of traumatic and non-traumatic origin: a population-based study. Acta Orthop Scand (2003) 0.92
Whiplash injuries: diagnosis and early management. The Swedish Society of Medicine and the Whiplash Commission Medical Task Force. Eur Spine J (2008) 0.91
Pigment epithelium-derived factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor microenvironment. Neoplasia (2010) 0.91
Prostate tissue stiffness as measured with a resonance sensor system: a study on silicone and human prostate tissue in vitro. Med Biol Eng Comput (2006) 0.91
Replication-competent Ad11p vector (RCAd11p) efficiently transduces and replicates in hormone-refractory metastatic prostate cancer cells. Hum Gene Ther (2009) 0.90
Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer. Int J Cancer (2002) 0.89
Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants. PLoS One (2013) 0.89
Inhibition of the epidermal growth factor receptor enhances castration-induced prostate involution and reduces testosterone-stimulated prostate growth in adult rats. Prostate (2007) 0.89
Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy. Hum Pathol (2012) 0.88
H HRMAS NMR Derived Bio-markers Related to Tumor Grade, Tumor Cell Fraction, and Cell Proliferation in Prostate Tissue Samples. Biomark Insights (2011) 0.88
Expression of erythropoietin and its receptor in human renal cell carcinoma. Tumour Biol (2009) 0.88
Evaluation of CD31 (PECAM-1) expression using tissue microarray in patients with renal cell carcinoma. Tumour Biol (2007) 0.88
Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy. Prostate (2005) 0.88
The stroma-a key regulator in prostate function and malignancy. Cancers (Basel) (2012) 0.88
Androgen action via testicular arteriole smooth muscle cells is important for Leydig cell function, vasomotion and testicular fluid dynamics. PLoS One (2010) 0.88
Linkage analysis of prostate cancer susceptibility: confirmation of linkage at 8p22-23. Hum Genet (2003) 0.88
Castration rapidly decreases local insulin-like growth factor-1 levels and inhibits its effects in the ventral prostate in mice. Prostate (2006) 0.87
-160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. Int J Cancer (2004) 0.87
Living after radical prostatectomy for localized prostate cancer: a qualitative analysis of patient narratives. Acta Oncol (2005) 0.87
Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation. Lab Invest (2010) 0.87
Establishment and validation of an in vitro co-culture model to study the interactions between bone and prostate cancer cells. Clin Exp Metastasis (2009) 0.86
TRAF6 stimulates the tumor-promoting effects of TGFβ type I receptor through polyubiquitination and activation of presenilin 1. Sci Signal (2014) 0.86
Nervous tissue damage markers in cerebrospinal fluid after cervical spine injuries and whiplash trauma. J Neurotrauma (2003) 0.86
Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin Cancer Res (2006) 0.86
Resonance sensor measurements of stiffness variations in prostate tissue in vitro--a weighted tissue proportion model. Physiol Meas (2006) 0.86
Nuclear androgen receptors recur in the epithelial and stromal compartments of malignant and non-malignant human prostate tissue several months after castration therapy. Prostate (2007) 0.85
Chronic prostatic infection and inflammation by Propionibacterium acnes in a rat prostate infection model. PLoS One (2012) 0.85
Testosterone-stimulated growth of the rat prostate may be driven by tissue hypoxia and hypoxia-inducible factor-1alpha. J Endocrinol (2008) 0.85
Localized expression of angiopoietin 1 and 2 may explain unique characteristics of the rat testicular microvasculature. Biol Reprod (2003) 0.85
Analysis of the macrophage scavenger receptor 1 gene in Swedish hereditary and sporadic prostate cancer. Prostate (2004) 0.85
Early diagnosis and treatment is crucial for neurological recovery after surgery for metastatic spinal cord compression in prostate cancer. Acta Oncol (2012) 0.85